We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

BioPerfectus Technologies

Bioperfectus Technologies Co., Ltd. is one of the leading molecular diagnostic solution providers in the global in-vi... read more Featured Products: More products

Download Mobile App





BioPerfectus Presents Total PCR Solution at Medlab Middle East 2023

By LabMedica International staff writers
Posted on 08 Feb 2023

Jiangsu Bioperfectus Technologies Co. More...

, Ltd. (Shanghai, China) is presenting its Total PCR Solution at Medlab Middle East 2023 that can improve operational and cost efficiency, optimize workflow, and increase performance at every opportunity.

Bioperfectus Total PCR Solution offers holistic products of extraction systems, extraction reagents, real-time PCR systems, and RT-PCR reagents. These products could cover PCR detection workflow and assure the users with reassuring results by validated performance. At Medlab Middle East 2023, Bioperfectus is highlighting the STC-96A Plus Real-Time PCR system that is a more-than-ever flexible, efficient and reliable breakthrough in the real-time PCR analysis of gene expression and genetic variation. Bioperfectus is also highlighting the SAW-96 automated nucleic acid extraction workstation, an in-vitro diagnostic medical device that integrates cutting-edge mechanical, electronic, and software technologies. In addition, Bioperfectus is showcasing the SSNP-2000B nucleic acid extraction system, which integrates new technologies such as machine, electricity and computer software to enable automatic nucleic acid extraction of 32 samples maximum in one time.

Among its other nucleic acid extraction solutions, Bioperfectus is highlighting the SMPE-960 nucleic acid extraction system which integrates cutting-edge mechanical, electronic and software technologies to enable automated extraction of nucleic acids from samples. Featuring a modular structure, the SMPE-960 can extract nucleic acids from 1-96 samples in three independently operating modules at the same time. Bioperfectus is also providing a glimpse of its new products to be launched soon, including the SSNP-A6 nucleic acid extraction system that can extract nucleic acids from 96 samples simultaneously to meet the requirement for high throughput laboratories, alongside the SSP-1196 automatic sample preparing system that enables automated capping, scanning of barcode, transfer of sample liquid to the extraction plate, decapping and ready to extraction.

Related Links:
Jiangsu Bioperfectus Technologies Co., Ltd.


New
Gold Member
Automatic Hematology Analyzer
CF9600
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Total Laboratory Automation Solution
SATLARS Mini T8
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.